The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy
暂无分享,去创建一个
[1] Jinming Huang,et al. Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. , 2002, Journal of the American Chemical Society.
[2] J. Eckman,et al. Thrombogenesis in sickle cell disease. , 2001, The Journal of laboratory and clinical medicine.
[3] J. Bischof,et al. Transgenic sickle mice have vascular inflammation. , 2003, Blood.
[4] E. Verrier. The vascular endothelium: friend or foe? , 1993, The Annals of thoracic surgery.
[5] Jenifer L. Breshears. Silent Cerebral Infarcts in Sickle Cell Anemia: A Risk Factor Analysis. , 2000 .
[6] L. McIntire,et al. Adhesion of sickle red blood cells and damage to interleukin-1 beta stimulated endothelial cells under flow in vitro. , 1996, Blood.
[7] D. Winter,et al. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. , 2001, The Journal of surgical research.
[8] R. Hebbel,et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. , 2003, Blood.
[9] R. Hebbel,et al. Sickle Cell Disease: Basic Principles and Clinical Practice , 1994 .
[10] S. Moore,et al. Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.
[11] G. Vercellotti,et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. , 2000, Blood.
[12] V. Kalra,et al. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. , 1998, Blood.
[13] D. S. Mcleod,et al. Angiogenic factors in human proliferative sickle cell retinopathy , 1999, The British journal of ophthalmology.
[14] Scott T. Miller,et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. , 1999, Pediatrics.
[15] D. D. Shock,et al. Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions. , 1996, Blood.
[16] J. Grande,et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. , 2001, The American journal of pathology.
[17] E. Wayner,et al. Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.
[18] F. Pavalko,et al. Vascular endothelial cell activation and permeability responses to thrombin. , 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[19] J. White,et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. , 1980, The Journal of clinical investigation.
[20] J. Castaigne,et al. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises. , 1984, Agents and actions. Supplements.
[21] Steven M Holland,et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. , 2003, The Journal of clinical investigation.
[22] E. Wayner,et al. Integrin alpha 4 beta 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia , 1993 .
[23] A. Koch,et al. Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. , 1999, Arthritis and rheumatism.
[24] A. Kumar,et al. Inhibition of plasma‐mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD‐containing peptides , 1996, American journal of hematology.
[25] A. Duits,et al. Neutrophil activation in sickle cell disease , 1999, Journal of leukocyte biology.
[26] R. Adams,et al. Sickle cell disease: The neurological complications , 2002, Annals of neurology.
[27] J. White,et al. Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. , 1987, Blood.
[28] J. Panepinto,et al. Pathophysiology of Stroke in Sickle Cell Disease , 2004, Microcirculation.
[29] F. Kuypers,et al. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. , 2000, Blood.
[30] A. Varki,et al. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. , 2002, Blood.
[31] M. Endres,et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice , 2002, Brain Research.
[32] B. Setty,et al. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. , 2002, Blood.
[33] R. Nagel,et al. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. , 2000, Blood.
[34] S. Embury. The Not‐So‐Simple Process of Sickle Cell Vasoocclusion , 2004, Microcirculation.
[35] G. Wise,et al. Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures. , 1979, Blood.
[36] A. Grigg,et al. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. , 2001, Blood.
[37] J. Witztum,et al. Epoxyisoprostane and Epoxycyclopentenone Phospholipids Regulate Monocyte Chemotactic Protein-1 and Interleukin-8 Synthesis , 2002, The Journal of Biological Chemistry.
[38] J. Gore,et al. Demonstration of endothelial adhesion of sickle cells in vivo: a distinct role for deformable sickle cell discocytes. , 1992, Blood.
[39] N. Perelman,et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. , 2003, Blood.
[40] O. Castro,et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.
[41] M. Khademi,et al. Renal angiography in sickle-cell disease. A preliminary report correlating the angiographic and urographic changes in sickle-cell nephropathy. , 1973, Radiology.
[42] L. McIntire,et al. Perfusion with sickle erythrocytes up-regulates ICAM-1 and VCAM-1 gene expression in cultured human endothelial cells. , 2000, Blood.
[43] E. Vichinsky,et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. , 1997, Blood.
[44] G. Merault,et al. Morphological features of the human umbilical vein in normal, sickle cell trait, and sickle cell disease pregnancies. , 1999, Human pathology.
[45] M. Gladwin,et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. , 2003, The Journal of clinical investigation.
[46] L. McIntire,et al. Sickle erythrocytes increase prostacyclin and endothelin‐1 production by cultured human endothelial cells under flow conditions , 2002, European journal of haematology.
[47] C. Dampier,et al. Arachidonic acid metabolites are involved in mediating red blood cell adherence to endothelium. , 1995, The Journal of laboratory and clinical medicine.
[48] J. Scott,et al. Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. , 1996, Blood.
[49] Scott T. Miller,et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.
[50] C. Moertel,et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. , 1998, Blood.
[51] J. Eckman,et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion. , 1993, Blood.
[52] A. Duits,et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. , 1996, Clinical immunology and immunopathology.
[53] R. Hebbel,et al. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. , 1999, Biochimica et biophysica acta.
[54] R. Rojer,et al. Molgramostim to treat SS-sickle cell leg ulcers , 1995, The Lancet.
[55] M. Gladwin,et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] C. B. Alexander,et al. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. , 2003, The Journal of biological chemistry.
[57] D. S. Mcleod,et al. Inhibition of TNF-α–induced Sickle RBC Retention in Retina by a VLA-4 Antagonist , 2001 .
[58] Richard A.O. Montes,et al. Sickle erythrocyte adherence to endothelium at low shear: Role of shear stress in propagation of vaso‐occlusion , 2002, American journal of hematology.
[59] K. Pritchard,et al. L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease , 2003, Circulation.
[60] H. Hydén,et al. A receptor for phosphatidylserine-specific clearance of apoptotic cells , 2000, Nature.
[61] J. Eckman,et al. Double-stranded RNA induces sickle erythrocyte adherence to endothelium: a potential role for viral infection in vaso-occlusive pain episodes in sickle cell anemia. , 1995, Blood.
[62] I. Kushner,et al. Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.
[63] J. Greenberg,et al. Trial of low doses of aspirin as prophylaxis in sickle cell disease. , 1983, The Journal of pediatrics.
[64] M. Boisseau,et al. [Hemostasis]. , 2020, Revue de laryngologie - otologie - rhinologie.
[65] B. Ewenstein,et al. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. , 1999, Blood.
[66] G. Kojda,et al. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. , 2002, Cardiovascular research.
[67] H. Meiselman,et al. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. , 1996, Blood.
[68] B. Setty,et al. Thrombophilia in sickle cell disease: the red cell connection. , 2001, Blood.
[69] P. Frenette. Sickle Cell Vasoocclusion: Heterotypic, Multicellular Aggregations Driven by Leukocyte Adhesion , 2004, Microcirculation.
[70] H. Farber,et al. Endothelin-1 production during the acute chest syndrome in sickle cell disease. , 1997, American journal of respiratory and critical care medicine.
[71] R. Korthuis,et al. Physiologic mechanisms of postischemic tissue injury. , 1995, Annual review of physiology.
[72] O. Castro,et al. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.
[73] J. Dachary-Prigent,et al. Phosphatidylserine‐related adhesion of human erythrocytes to vascular endothelium , 1999, British journal of haematology.
[74] J. Scott,et al. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin , 2000, British journal of haematology.
[75] E. Rubin,et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. , 1995, The Journal of clinical investigation.
[76] D. Lefer,et al. Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: Role of endothelial cell nitric oxide synthase , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[77] D. Lefer,et al. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. , 1998, Free radical biology & medicine.
[78] P. Hogg,et al. Control of Von Willebrand Factor Multimer Size by Thrombospondin-1 , 2001, The Journal of experimental medicine.
[79] A. Varki,et al. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. , 2001, Blood.
[80] Xiao-Yu Song,et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.
[81] P. Klug,et al. Endothelial cell and vascular damage in the sickle cell disorders. , 1982, Blood cells.
[82] R. Hebbel,et al. CD36-positive stress reticulocytosis in sickle cell anemia. , 1996, The Journal of laboratory and clinical medicine.
[83] J. Loscalzo,et al. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. , 2000, Circulation.
[84] R. Nagel,et al. Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist. , 2001, Investigative ophthalmology & visual science.
[85] S. Raines,et al. Priapism associated with sickle cell disease. , 1962, The Journal of urology.
[86] S. Hazen,et al. Peroxidases inhibit nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions. , 2001, Biochemistry.
[87] A. Duits,et al. Levels of Endothelial, Neutrophil and Platelet-Specific Factors in Sickle Cell Anemia Patients during Hydroxyurea Therapy , 1999, Acta Haematologica.
[88] T. Wun,et al. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. , 2002, Clinical and laboratory haematology.
[89] G. Vercellotti,et al. Reperfusion injury pathophysiology in sickle transgenic mice. , 2000, Blood.
[90] M. Gladwin,et al. The Perfusion Paradox and Vascular Instability in Sickle Cell Disease , 2004, Microcirculation.
[91] J. Hofrichter,et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. , 1996, Blood.
[92] S. Sowemimo-Coker,et al. Effects of normal and sickle erythrocytes on prostacyclin release by perfused human umbilical cord veins , 1992, American journal of hematology.
[93] K. Preissner,et al. Vascular protease receptors: integrating haemostasis and endothelial cell functions , 2000, The Journal of pathology.
[94] J. Morris,et al. Stroke in a cohort of patients with homozygous sickle cell disease. , 1992, The Journal of pediatrics.
[95] J. Stuart,et al. Subclinical ischaemic episodes during the steady state of sickle cell anaemia. , 1992, Journal of clinical pathology.
[96] L. Parise,et al. Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin. , 2001, Blood.
[97] J. Maclouf,et al. Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium. , 1986, The Journal of laboratory and clinical medicine.
[98] C. Pegelow,et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. , 2002, The Journal of pediatrics.
[99] J. Moake,et al. Unusually large von willebrand factor multimers preferentially promote young sickle and nonsickle erythrocyte adhesion to endothelial cells , 1993, American journal of hematology.
[100] R. Hebbel,et al. Modulation of endothelial cell activation in sickle cell disease: a pilot study. , 2001, Blood.
[101] R. Hebbel,et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.
[102] R. Silverstein,et al. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.
[103] J. Scott,et al. The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. , 1999, Blood.
[104] A. Shah. Vascular endothelium. , 1992, British journal of hospital medicine.
[105] B. Setty,et al. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. , 1999, Blood.
[106] P. Gane,et al. The nonexpression of CD 36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia , 2001 .
[107] M L Terrin,et al. Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent , 1996, Medicine.
[108] D. Ribatti,et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. , 1999, Blood.
[109] G. Truskey,et al. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin. , 1998, The Journal of clinical investigation.
[110] R. Hebbel,et al. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease , 1996, American journal of hematology.
[111] C. Thomas,et al. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). , 1990, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.
[112] R. Nagel,et al. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. , 1993, Blood.
[113] J. Zhan,et al. Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. , 1994, Blood.
[114] T. Pearson,et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. , 1998, Blood.
[115] C. Srodes,et al. An unusual pattern of neutrophil kinetics in sickle cell anemia. , 1973, Blood.
[116] W. Murphy,et al. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. , 1989, East African medical journal.
[117] J. Lawler,et al. Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. , 1997, Blood.
[118] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[119] R. Schmid,et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. , 1998, The Journal of clinical investigation.
[120] R. Hebbel,et al. Tissue factor expression by endothelial cells in sickle cell anemia. , 1998, The Journal of clinical investigation.
[121] J. Geng,et al. N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo , 2002, Inflammation Research.
[122] J. Prchal,et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. , 2001, Blood.
[123] R. Weinstein,et al. Sickle erythrocytes inhibit human endothelial cell DNA synthesis. , 1990, Blood.
[124] D. Yee,et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. , 2002, Cancer research.
[125] M. Mosseri,et al. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. , 1993, American heart journal.
[126] H. Cate,et al. Low‐intensity oral anticoagulation in sickle‐cell disease reverses the prethrombotic state: promises for treatment? , 1995, British journal of haematology.
[127] R. Hebbel,et al. Autoxidation, dehydration, and adhesivity may be related abnormalities of sickle erythrocytes. , 1989, The American journal of physiology.
[128] S. Albelda,et al. Integrins and other cell adhesion molecules , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[129] B. Setty,et al. Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol. , 1996, The Journal of laboratory and clinical medicine.
[130] F. Mach,et al. Statins: the new aspirin? , 2002, Cellular and Molecular Life Sciences CMLS.
[131] M. Gladwin,et al. Divergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease , 2003, Circulation.
[132] L. Parise,et al. Sickle cell adhesion to laminin : Potential role for the α5 chain , 1998 .
[133] L. Parise,et al. Sickle cell adhesion to laminin: potential role for the alpha5 chain. , 1998, Blood.
[134] F. Galactéros,et al. Fibrinogen, a modulator of erythrocyte adhesion to vascular endothelium. , 1983, The Journal of laboratory and clinical medicine.
[135] J. Eaton,et al. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. , 1980, The New England journal of medicine.
[136] P. V. Ichinsky,et al. Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease , 2000 .
[137] J. Stuart,et al. Effects of density and of dehydration of sickle cells on their adhesion to cultured endothelial cells , 1996, American journal of hematology.
[138] D. McIntire,et al. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. , 1994, The New England journal of medicine.
[139] R. Nagel,et al. Monoclonal antibodies to αVβ3 (7E3 and LM609) inhibit sickle red blood cell–endothelium interactions induced by platelet-activating factor , 2000 .
[140] K. Ataga,et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. , 2001, JAMA.
[141] W. Frazier. Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells , 1987, The Journal of cell biology.
[142] M. Hughson,et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. , 2001, Archives of pathology & laboratory medicine.
[143] J. Elion,et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. , 2002, Blood.
[144] J. Salvaggio,et al. Long-term anti-coagulation in sickle-cell disease. A clinical study. , 1963, The New England journal of medicine.
[145] J. Eckman,et al. Sickle erythrocyte adherence to large vessel and microvascular endothelium under physiologic flow is qualitatively different. , 1992, The Journal of laboratory and clinical medicine.
[146] R. Hebbel,et al. Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice , 2018 .
[147] J. Reisch,et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. , 1998, Blood.
[148] P. Libby,et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.
[149] M. Telfer,et al. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. , 1998, Blood.
[150] P. Adegboyega,et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. , 2002, Human pathology.
[151] M. Ho,et al. Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. , 2000, Blood.
[152] F. Kirkham,et al. Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia , 2000, British journal of haematology.
[153] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[154] T. Wun,et al. Platelet-erythrocyte adhesion in sickle cell disease. , 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[155] P. Gane,et al. The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia. , 2001, Blood.
[156] S. Rothman,et al. Sickle cell anemia and central nervous system infarction: A neuropathological study , 1986, Annals of neurology.
[157] B. Setty,et al. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. , 1996, Blood.
[158] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.
[159] R. Hebbel,et al. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. , 1999, Blood.
[160] J. Loscalzo,et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. , 1998, Blood.
[161] M. Steinberg,et al. Modulation of erythrocyte-endothelial interactions and the vasocclusive severity of sickling disorders. , 1981, Blood.
[162] R. Nagel,et al. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. , 1986, Blood.
[163] A. Morelli,et al. NCX-4016 (NO-Aspirin) Inhibits Lipopolysaccharide-Induced Tissue Factor Expression In Vivo: Role of Nitric Oxide , 2002, Circulation.
[164] C. Dampier,et al. Splenic Arteries and Veins in Pediatric Sickle Cell Disease , 2001, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[165] B. Setty,et al. Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology. , 2002, The Journal of laboratory and clinical medicine.
[166] J. Rosa,et al. Clinical manifestations and erythrocyte adhesion to endothelium in sickle cell syndrome , 1985, American journal of hematology.
[167] J. Moake,et al. Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow. , 1987, The Journal of clinical investigation.
[168] C. Dampier,et al. Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. , 2001, Blood.
[169] F. Kuypers,et al. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. , 2001, Blood.
[170] L. Dobrucki,et al. Increased Nitric Oxide Bioavailability in Endothelial Cells Contributes to the Pleiotropic Effect of Cerivastatin , 2002, Circulation.
[171] J. Laver,et al. Granulocytosis causing sickle-cell crisis , 1998, The Lancet.
[172] T. Pearson,et al. Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF) , 1992, British journal of haematology.
[173] J. Weil,et al. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium , 2000, American journal of hematology.
[174] K. Koh. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. , 2000, Cardiovascular research.
[175] L. Parise,et al. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. , 2001, The Journal of clinical investigation.
[176] R. Hebbel. Adhesive interactions of sickle erythrocytes with endothelium. , 1997, The Journal of clinical investigation.
[177] E. Evans,et al. Sickle erythrocyte adherence to vascular endothelium. Morphologic correlates and the requirement for divalent cations and collagen-binding plasma proteins. , 1985, The Journal of clinical investigation.
[178] B. Coller,et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[179] M. Fabry,et al. In Vivo Studies of Sickle Red Blood Cells , 2004, Microcirculation.
[180] D. Faller,et al. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. , 1995, The Journal of clinical investigation.
[181] A. Takeshita,et al. Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. , 2002, American journal of physiology. Heart and circulatory physiology.
[182] F. Ofosu,et al. Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patients , 1992, British journal of haematology.
[183] M. Gladwin,et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease , 2002, Nature Medicine.
[184] J. L. Goodman,et al. Potentiated adherence of sickle erythrocytes to endothelium infected by virus. , 1987, The Journal of clinical investigation.
[185] R. Nagel,et al. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[186] M. Steinberg,et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. , 1997, Blood.
[187] Subrata Ghosh,et al. Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.
[188] WILLIAM H. FRISHMAN,et al. Role of Infection in Atherosclerosis and Coronary Artery Disease: A New Therapeutic Target? , 1999, Heart disease.
[189] P. Lauf,et al. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. , 1994, Blood.
[190] Scott T. Miller,et al. Prediction of adverse outcomes in children with sickle cell disease. , 2000, The New England journal of medicine.
[191] M. Telen,et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. , 2003, Blood.
[192] T. Sugihara,et al. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. , 1992, Blood.
[193] Marie-Luise Brennan,et al. Myeloperoxidase Functions as a Major Enzymatic Catalyst for Initiation of Lipid Peroxidation at Sites of Inflammation* , 2002, The Journal of Biological Chemistry.